Key Takeaways
Organoid manufacturing requires bioreactor designs that go beyond traditional monolayer cell culture and bulk cell-expansion models.
Oxygen transport, nutrient gradients, waste removal, and mechanical forces are central challenges in scaling three-dimensional organoid systems.
Clinical-grade organoid production depends on defined materials, xeno-free or animal-free alternatives, reproducible handling, and reduced operator-dependent variability.
Future organoid bioreactors will need to integrate culture control, perfusion, matrix compatibility, automation, and quality-linked process monitoring.
Organoid-based therapies and translational applications will require manufacturing platforms that make biological self-organization reproducible, measurable, and scalable.
Introduction: When the Product Has Structure
Biomanufacturing has long been organized around expansion, control, and consistency: grow the cells, maintain the environment, harvest the product, and demonstrate that the process can be reproduced. Organoids complicate that model because the product is an organized biological structure. These three-dimensional, self-organizing cell cultures can model diverse tissues and organs, and their value depends on their ability to recapitulate aspects of native tissue structure and function.1,2
That distinction changes the manufacturing problem. A process that expands cells efficiently may still fall short if it disrupts morphology, alters differentiation, or produces structures that vary too widely from batch to batch. As organoid production moves toward translational and clinical use, engineering strategies are increasingly judged by whether they improve reproducibility and scalability.3
The barriers are already visible. Reproducibility can be affected by biologically variable materials with poorly defined properties and by stochastic morphogenetic processes linked to uncontrolled spatial organization. Scalability can be constrained by low-productivity culture platforms and labor-intensive handling steps.
Bioreactor design therefore becomes central to the future of organoid manufacturing. The reactor must do more than provide culture volume. It must help control oxygenation, nutrient delivery, waste removal, fluid flow, mechanical inputs, matrix interactions, and spatial organization while preserving the architecture that gives the organoid its biological value.
From Organoid Culture to Organoid Manufacturing
The shift from organoid culture to organoid manufacturing is already emerging in specific systems, even if the field remains early and application-specific. In human pancreas organoids, investigators developed a standardized good manufacturing practice (GMP)-compliant process for scalable production and described the work as a milestone toward GMP-compliant human pancreas organoid production and eventual clinical application as a type 1 diabetes therapy.4
The process changes highlight how quickly organoid production becomes an engineering problem. The investigators removed operator-dependent pancreatic duct picking steps, introduced mechanical dissociation, replaced R-spondin-1 conditioned medium with recombinant R-spondin-1 to define medium composition, and implemented a GMP-compliant freezing protocol.
Similar movement toward clinical-grade production is visible in retinal organoid work. A clinical-grade retinal organoid study reported a xeno-free, current good manufacturing practice–compliant induced pluripotent stem cell (iPSC)-derived three-dimensional retinal differentiation protocol for producing transplantable photoreceptor precursor cells.5
These examples show organoid production beginning to move from bespoke laboratory workflows toward clinical-grade processes built around defined materials, reproducible handling, and scalable production. They also clarify why organoid bioreactors cannot be designed only as larger culture containers. They must become tools for reducing uncontrolled variation and making three-dimensional maturation more consistent.
Why Conventional Culture Logic Is Not Enough
Organoid manufacturing cannot be treated as a simple extension of monolayer cell culture. Their generation and maturation require optimization of environmental cues, such as oxygenation, mechanical and fluidic activation, and nutrient gradients.2
The culture system must therefore shape the biological environment, not merely maintain viability. Bioreactors can provide features that are absent from static two-dimensional culture, including increased fluid flow, gradients of signaling molecules and growth factors, and forms of stimulation.
That need has led to a diverse set of organoid bioreactor approaches, including stirred bioreactors, rotating wall vessels, microfluidic bioreactors, and electrical stimulation bioreactors. Each offers a different way to influence mixing, flow, stimulation, nutrient exchange, and environmental control.
For manufacturing, the diversity of these systems is significant. Organoid production may not converge quickly around one universal reactor platform. Reactor design will likely need to reflect the biology of the tissue, the intended application, and the quality attributes that define success for a given product. A retinal organoid, pancreatic organoid, vascular organoid, and cardiac organoid may all require three-dimensional culture, but the cues and structural features required for maturation may differ.
Conventional scale-up assumptions begin to break down when the product’s architecture is as important as its yield. Increasing culture volume does not automatically solve problems of spatial organization, transport, differentiation, reproducibility, or long-term culture control. The bioreactor must shape the environment around the organoid while preserving the structure within it.
The Transport Problem: Oxygen, Nutrients, and Waste
Transport is one of the most immediate technical barriers in three-dimensional culture. Cells in monolayer culture are exposed more directly to the surrounding medium, while cells embedded within a three-dimensional aggregate experience a more complex microenvironment. Oxygen, nutrients, soluble factors, and waste products must move through the structure, and that movement can become limiting as aggregate size, density, and culture duration increase.6
Oxygen is especially important because it plays a role in the proliferation, differentiation, and function of three-dimensional aggregates. The oxygenation requirements of a culture are shaped by cell seeding density, culture media height, cellular oxygen consumption rate, and aggregate dimensions, all of which can affect reproducibility and biological performance.
Static culture systems can intensify this challenge. In gas-impermeable culture systems, static culture can create steep oxygen and nutrient gradients, shifting cells or aggregates into different metabolic, growth, or differentiation states. Three-dimensional aggregates cultured in plastic can develop core regions of hypoxia or anoxia, with risk increasing as media height, aggregate dimensions, and oxygen consumption rates increase.
For organoid manufacturing, oxygenation becomes a design parameter rather than a background culture condition. A system that produces viable organoids at small scale may not remain reliable as organoid size, batch density, or culture duration increases. The central question is whether oxygen and nutrients reach the organoid in a way that supports the intended structure, differentiation state, and function throughout the culture period.
Waste removal is part of the same transport problem. Organoid-on-chip and vascularization strategies are being explored in part because organoid systems can be limited by the absence of functional and perfusable vasculature. Stable perfusable architectures can support oxygen and nutrient delivery, waste removal, and maturation beyond early developmental stages..
Organoid bioreactors must therefore manage the internal microenvironment of a three-dimensional product, not only the bulk conditions of the surrounding medium. Mixing, perfusion, fluid flow, and vascular-like architectures all influence whether the structure being manufactured remains viable, reproducible, and functionally meaningful.
Mixing Without Damage
Improving transport through motion creates a related challenge: mechanical control. Organoid systems often need fluid movement, exchange, and stimulation, but the same physical forces that improve oxygen and nutrient delivery may also alter the structures being manufactured. The goal is to generate enough movement to support culture performance without undermining morphology, spatial organization, or maturation.
Different reactor formats approach this balance in different ways. Stirred systems, rotating wall vessels, microfluidic systems, and stimulation-based systems each create distinct culture environments. Their value depends not only on whether they support cell survival or expansion but also on whether they provide conditions compatible with three-dimensional organization and tissue-like maturation.
Mechanical and fluidic conditions can also become sources of variability. Organoid processes already face challenges from biologically variable materials, stochastic morphogenesis, and uncontrolled spatial organization. Poorly controlled movement or stimulation can add another layer of inconsistency.
In many cell culture contexts, stronger mixing may be viewed as a route to better homogeneity. For organoids, bulk homogeneity is not enough. Excessive or poorly matched mechanical input can conflict with the need to preserve three-dimensional architecture. A reactor that improves transport at the expense of structure may compromise the very feature that makes the organoid valuable.
Future reactor designs will need to balance transport and protection. They must move oxygen, nutrients, waste products, and signaling molecules effectively while maintaining the physical conditions required for organoids to form, mature, and remain consistent. Mechanical and fluidic inputs will need to become defined process variables linked to product quality.2,3
Matrices, Hydrogels, and Translational Compatibility
Organoid reactor architecture extends beyond the vessel itself. The physical and biochemical environment surrounding the cells helps shape how organoids form, mature, and maintain their structure. Matrices, hydrogels, scaffolds, and media components are therefore part of the manufacturing system.3,8
This is a particular challenge for clinical translation because many organoid workflows have relied on materials that are useful in research but less suitable for reproducible, clinically oriented production. In vascular organoid culture, Matrigel is widely used, but its animal origin has been identified as a limitation for translational potential and reproducibility.
Animal-free and more defined materials are becoming part of the manufacturing solution. A study evaluating animal-free alternatives for Matrigel in human iPSC-derived blood vessel organoid culture identified vitronectin as a suitable replacement for Matrigel in iPSC culture and expansion and found that fibrin-based hydrogels supported vascular organoid differentiation and vascular network formation.8
Retinal organoid production illustrates the same pressure toward defined, clinically compatible inputs. A clinical-grade retinal organoid study reported a xeno-free, current good manufacturing practice–compliant iPSC-derived three-dimensional retinal differentiation protocol and replaced animal-derived or nonclinical reagents, including dispase, Matrigel, and fetal bovine serum, with xeno-free alternatives.5
Clinical translation will require culture environments that are more defined, controllable, and compatible with quality expectations. The matrix or scaffold cannot be treated as a passive background ingredient if it contributes to variability, affects structure, or creates translational barriers.
Scale-up will depend not only on increasing culture volume but also on ensuring that the materials used to support three-dimensional organization can be sourced, controlled, documented, and reproduced. For organoid manufacturing, the reactor, medium, matrix, flow environment, and handling strategy all contribute to the final product.
Automation, Scale, and Quality Control
Organoid production often begins as a highly skilled laboratory workflow, but clinical and industrial manufacturing cannot depend indefinitely on artisanal handling. Manual selection, subjective visual judgment, and labor-intensive manipulation may be feasible in research settings but become sources of variability and bottlenecks as production needs increase.
The pancreas organoid study illustrates the transition from manual culture to more standardized production. The investigators removed operator-dependent pancreatic duct picking steps, introduced mechanical dissociation, replaced R-spondin-1 conditioned medium with recombinant R-spondin-1 to define medium composition, and implemented a GMP-compliant freezing protocol.4
Retinal organoid production provides another example. A directed, small molecule–based, serum-free microwell platform generated uniform self-assembled three-dimensional spheres from dissociated human pluripotent stem cells and eliminated time-consuming manual microdissection.9
Automation and standardization reduce more than labor. They help convert tacit handling practices into defined, repeatable operations. In organoid production, variation in starting material, matrix composition, aggregate size, dissociation, feeding, oxygenation, and handling can influence the structure that emerges. A scalable process must therefore reduce operator-dependent steps and control the conditions that shape organoid formation.
These manufacturing concerns connect directly to quality and chemistry, manufacturing, and controls (CMC). Clinical-grade stem cell production requires GMP-compliant facilities, protocols, production systems, and quality-checking mechanisms. For organoid-based products, those expectations must be applied to processes that generate organized three-dimensional structures rather than relatively uniform cell populations alone.10
A general quality-control strategy for gene and cell therapy products can include identity or concentration determination, impurity testing, potency, stability, and safety evaluations. Quality strategies should also be individualized according to the characteristics of the product and its manufacturing or purification methods.
That individualized approach is especially relevant for organoids because different systems may require different definitions of acceptability. The attributes that matter for a retinal organoid product may not be identical to those that matter for a pancreatic, vascular, intestinal, or cardiac organoid system. A quality strategy may need to account for the intended tissue, starting cell source, differentiation process, matrix or scaffold, culture format, and intended clinical or translational use.11
Advanced therapy manufacturing depends on linking critical quality attributes to safety and efficacy and using those attributes to define release specifications and stability profiles. Manufacturing process steps should be controlled through process parameters and in-process controls to ensure specifications can be achieved.
For organoid manufacturing, this raises the central CMC question: what makes a living three-dimensional structure acceptable as a product? Identity, purity, viability, potency, sterility, and safety will remain important, but organoid-specific quality may also require ways to assess morphology, spatial organization, differentiation, maturation, and functional performance. The need for individualized quality strategies is clear, while the exact release framework for organoid-based products remains an emerging challenge.
Quality by design (QbD) offers one useful lens for this challenge. A review of current good manufacturing practice–oriented large-scale expansion of human iPSCs in bioreactors argues that industrial scale-up of high-quality iPSCs should be designed using QbD principles. Although iPSC expansion is not the same as organoid manufacturing, upstream variability in pluripotent stem cell production can shape downstream differentiation and three-dimensional product formation.12
The long-term CMC challenge is to connect process inputs to organoid outputs. Oxygenation, nutrient gradients, matrix composition, aggregate size, fluidic conditions, handling steps, and freezing methods are potential sources of product variability. A mature organoid manufacturing strategy will need to define which parameters matter most for a given product and how they will be monitored, controlled, and linked to quality.
What Future Organoid Bioreactors Must Become
The next generation of organoid bioreactors will be defined by their ability to create controlled manufacturing environments for living architecture. Increasing output will matter only if the resulting structures remain reproducible, appropriately differentiated, functionally meaningful, and compatible with the intended translational or clinical use.
That future system will need to integrate functions that have often been treated separately in conventional culture workflows: oxygenation, nutrient delivery, waste removal, fluid flow, mechanical and fluidic cues, defined or clinically compatible materials, scalable handling, and quality-linked process control. These functions map directly onto the barriers already identified across organoid manufacturing, three-dimensional oxygenation, vascularization, materials, and advanced-therapy CMC.
No single architecture is likely to fit every organoid product. The diversity of existing bioreactor approaches suggests that platforms may remain tissue- and application-specific as the field matures. What should unify them is a shift from culture support to process definition. The reactor should make critical aspects of the culture environment measurable and controllable, including oxygenation, flow, media exchange, organoid size, matrix conditions, mechanical exposure, feeding schedules, and preservation steps. Those process parameters must then be connected to product attributes such as identity, viability, potency, stability, safety, morphology, maturation, and functional performance.
The field should therefore resist treating organoid bioreactors as a straightforward scale-up problem. The central manufacturing challenge is to make biological self-organization reproducible. That requires reactor architectures that manage transport without losing structure, provide stimulation without uncontrolled variability, support maturation without sacrificing scalability, and generate data that can support quality decisions.
Organoid manufacturing offers a window into the next phase of advanced therapy production, where spatial organization itself becomes part of the product. As organoid systems move toward more translational and clinical applications, bioreactors will need to evolve from culture vessels into integrated platforms for manufacturing living architecture.
References
1. Verstegen, Monique MA, et al. “Clinical applications of human organoids.” Nature Medicine. 31: 409–421 (2025).
2. Licata, Joseph P, et al. “Bioreactor technologies for enhanced organoid culture.” International Journal of Molecular Sciences. 24: 11427 (2023).
3. Kim, Dohui, et al. “From organoid culture to manufacturing: technologies for reproducible and scalable organoid production.” npj Biomedical Innovations. 3: 12 (2026).
4. Dossena, Marta, et al. “Standardized GMP-compliant scalable production of human pancreas organoids.” Stem Cell Research & Therapy. 11: 94 (2020).
5. Bohrer, Laura R, et al. “Production of clinical grade patient iPSC-derived 3D retinal organoids containing transplantable photoreceptor cells.” Stem Cell Research & Therapy. 16: 641 (2025).
6. Tse, Hubert M, et al. “The importance of proper oxygenation in 3D culture.” Frontiers in Bioengineering and Biotechnology. 9: 634403 (2021).
7. Menzani, Bianca, et al. “Vascularizing organoids-on-chip for perfused and personalized models.” Lab on a Chip. 26: 1798–1819 (2026).
8. Giles, Rachel, et al. “Animal-free alternatives for Matrigel in human iPSC-derived blood vessel organoid culture.” Scientific Reports. 15: 20091 (2025).
9. Rashidi, Hassan, et al. “Generation of 3D retinal tissue from human pluripotent stem cells using a directed small molecule-based serum-free microwell platform.” Scientific Reports. 12: 6646 (2022).
10. Chen, Shuang, et al. “Clinical translational research on stem cell products: prospects and challenges.” Signal Transduction and Targeted Therapy. 11: 178 (2026).
11. Yang, Quan-en, et al. “Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy.” BBA Advances. 7: 100151 (2025).
12. Rivera-Ordaz, Araceli, et al. “Critical analysis of cGMP large-scale expansion process in bioreactors of human induced pluripotent stem cells in the framework of quality by design.” BioDrugs. 35: 693–714 (2021).
